Sep 9, 2026 04:34PM

Jun 1, 2026 08:02AM

Jun 1, 2026 08:00AM

Mar 18, 2026 10:35AM

Mar 17, 2026 10:59AM

Mar 2, 2026 08:01AM

Mar 2, 2026 08:00AM Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Jul 8, 2025 08:03AM

Jul 8, 2025 08:00AM

Mar 12, 2024 08:00AM

Nov 9, 2023 08:00AM

Aug 8, 2023 08:00AM

Jun 29, 2023 07:03AM

Jun 29, 2023 07:00AM Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

May 9, 2023 08:00AM

Mar 6, 2023 08:00AM

Mar 6, 2023 07:31AM

Mar 6, 2023 07:30AM

Nov 7, 2022 08:00AM

Sep 28, 2022 08:01AM

Sep 28, 2022 08:00AM Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Aug 8, 2022 08:00AM

Aug 2, 2022 08:03AM

Aug 2, 2022 08:00AM

Jun 2, 2022 08:32AM

Jun 2, 2022 08:30AM

May 10, 2022 08:00AM

May 10, 2022 07:31AM Rallybio Corporation (RLYB) Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

May 10, 2022 07:30AM

Apr 4, 2022 08:00AM

Mar 15, 2022 08:00AM

Jan 18, 2022 08:00AM

Jan 6, 2022 08:00AM

Dec 1, 2021 07:04AM

Dec 1, 2021 07:00AM Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Nov 10, 2021 07:00AM

Sep 9, 2021 07:00AM

1,187,976 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All